Our preclinical studies have shown that the widely used antiparasitic drug albendazole has potent antiproliferative activity against colorectal cancer (CRC) and hepatocellular carcinoma (HCC). This trial was designed to evaluate albendazole in a small number of patients (n = 7) with either HCC or CRC and hepatic metastases refractory to other forms of therapy. Albendazole was given at 10 mg/kg/day orally in two divided doses for a period of 28 days. To follow the effect of treatment, tumor markers, carcinoembryonic antigen (CEA) or α-feto protein (AFP), were measured routinely in these patients. A range of hematological and biochemical indices were also serially measured to monitor bone marrow, kidney or liver toxicity. Albendazole therapy resulted in a decrease in CEA in 2 patients. In the remaining 5 with measurable tumor markers, serum CEA or AFP was stabilized in 3 patients, while in the other 2, after an initial stabilization (5–10 days), the markers began to increase. In the 7 patients completing the trial, albendazole was well tolerated and there were no significant changes in any hematological, kidney or liver function tests, but 3 patients were withdrawn for severe neutropenia which was probably contributory to the death of 1 patient. These data support our previous experimental results demonstrating that albendazole has antitumor effects.

1.
Hanjeet K, Mathias RG: The efficacy of treatment with albendazole. Acta Trop 1991;50:111–114.
2.
Lacey E: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988;18:885–936.
3.
Lacey E, Watson TR: Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: Correlation with in vitro tubulin polymerization assay. Biochem Pharmacol 1985;34:3603–3605.
4.
Rolin S, Souhaili-el amri H, Batt AM, Levy M, Bagrel D, Siest G: Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol Toxicol 1989;5:1–14.
5.
Kaplan O, Navon G, Lyon RC, Faustino PJ, Straks EJ, Cohen JS: Effects of 2-deoxyglucose on drug-sensitive human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 1990;50:544–551.
6.
Morris DL, Dykes PW, Dickson BE, Marriner SE, Bogan JA, Burrows FGO: Albendazole in hydatid disease. Br Med J 1983;286:103–104.
7.
Morris DL, Dykes PW, Marriner SE, Bogan JA, Burrows FGO, Skeene-Smith H, Clarkson MJ: Albendazole: Objective evidence of response in human hydatid disease. JAMA1984;253:2053–2057.
8.
Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett, in press.
9.
Quentmeir A, Schlag P, Hohenburger P, Schwarz V, Abel U: Assessment of serial CEA: Determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J Surg Oncol 1989;40:12–18.
10.
Adams WJ, Morris DL: CEA in the evaluation of therapy of primary and metastatic colorectal cancer. Aust NZ J Surg 1996;66:515–519.
11.
Borgers M, De Nollin S: Ultrastructural changes in Ascaris suum intestine after mebendazole treatment in vivo. J Parasitol 1975;60:110–122.
12.
Lacey E: Mode of action of benzimidazoles. Parasitol Today 1990;6:112–115.
13.
Friedman PA, Platzer EG: Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 1978;544:605–614.
14.
Ireland CM, Gull K, Gutteridge WE, Pogson CI: The interaction of benzimidazole carbamates with mammalian microtubule protein. Biochem Pharmacol 1979;17:2680–2682.
15.
Barrowman MM, Marriner SE, Bogan JA: The binding and subsequent inhibition of tubulin polymerization in Ascaris suum (in vitro) by benzimidazole anthelmintics. Biochem Pharmacol 1984;33:3037–3040.
16.
Wang IG, Liu XM, Kreis W, Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999;44:355–361.
17.
Shi Q, Chen K, Morris-Natschke SL, Lee KH: Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 1998;4:219–248.
18.
Bissel DM, Levine GA, Bissell MJ: Glucose metabolism by adult hepatocytes in primary culture and by cell lines from rat liver. Am J Physiol 1978;234:C122–C130.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.